Your browser doesn't support javascript.
loading
Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals.
Robbiani, Davide F; Gaebler, Christian; Muecksch, Frauke; Lorenzi, Julio C C; Wang, Zijun; Cho, Alice; Agudelo, Marianna; Barnes, Christopher O; Gazumyan, Anna; Finkin, Shlomo; Hagglof, Thomas; Oliveira, Thiago Y; Viant, Charlotte; Hurley, Arlene; Hoffmann, Hans-Heinrich; Millard, Katrina G; Kost, Rhonda G; Cipolla, Melissa; Gordon, Kristie; Bianchini, Filippo; Chen, Spencer T; Ramos, Victor; Patel, Roshni; Dizon, Juan; Shimeliovich, Irina; Mendoza, Pilar; Hartweger, Harald; Nogueira, Lilian; Pack, Maggi; Horowitz, Jill; Schmidt, Fabian; Weisblum, Yiska; Michailidis, Eleftherios; Ashbrook, Alison W; Waltari, Eric; Pak, John E; Huey-Tubman, Kathryn E; Koranda, Nicholas; Hoffman, Pauline R; West, Anthony P; Rice, Charles M; Hatziioannou, Theodora; Bjorkman, Pamela J; Bieniasz, Paul D; Caskey, Marina; Nussenzweig, Michel C.
Afiliação
  • Robbiani DF; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Gaebler C; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Muecksch F; Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
  • Lorenzi JCC; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Wang Z; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Cho A; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Agudelo M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Barnes CO; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
  • Gazumyan A; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Finkin S; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Hagglof T; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Oliveira TY; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Viant C; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Hurley A; Hospital Program Direction, The Rockefeller University, New York, NY 10065, USA.
  • Hoffmann HH; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
  • Millard KG; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Kost RG; Hospital Clinical Research Office, The Rockefeller University, New York, NY 10065, USA.
  • Cipolla M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Gordon K; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Bianchini F; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Chen ST; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Ramos V; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Patel R; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Dizon J; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Shimeliovich I; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Mendoza P; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Hartweger H; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Nogueira L; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Pack M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Horowitz J; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Schmidt F; Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
  • Weisblum Y; Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
  • Michailidis E; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
  • Ashbrook AW; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
  • Waltari E; Chan Zuckerberg Biohub, 499 Illinois Street, San Francisco, CA 94158, USA.
  • Pak JE; Chan Zuckerberg Biohub, 499 Illinois Street, San Francisco, CA 94158, USA.
  • Huey-Tubman KE; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
  • Koranda N; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
  • Hoffman PR; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
  • West AP; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
  • Rice CM; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
  • Hatziioannou T; Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
  • Bjorkman PJ; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
  • Bieniasz PD; Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
  • Caskey M; Howard Hughes Medical Institute.
  • Nussenzweig MC; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
bioRxiv ; 2020 May 22.
Article em En | MEDLINE | ID: mdl-32511384
ABSTRACT
During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-21-5. Here we report on 149 COVID-19 convalescent individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable half-maximal neutralizing titers ranging from undetectable in 33% to below 11000 in 79%, while only 1% showed titers >15000. Antibody cloning revealed expanded clones of RBD-specific memory B cells expressing closely related antibodies in different individuals. Despite low plasma titers, antibodies to three distinct epitopes on RBD neutralized at half-maximal inhibitory concentrations (IC50s) as low as single digit ng/mL. Thus, most convalescent plasmas obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: BioRxiv Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: BioRxiv Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos